|
1
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hamberg P, De Jong FA, Brandsma D, Verweij
J and Sleijfer S: Irinotecan-induced central nervous system
toxicity. Report on two cases and review of the literature. Acta
Oncol. 47:974–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sogabe S, Yuki S, Takano H, Kobayashi Y,
Nakatsumi H, Sasaki T, Kawamoto Y, Fukushima H, Iwanaga I, Uehata
Y, et al: A case of sigmoid colon cancer with temporary dysarthria
associated with irinotecan. Gan To Kagaku Ryoho. 38:1375–1377.
2011.(In Japanese). PubMed/NCBI
|
|
4
|
Gunturu KS, Yao X, Cong X, Thumar JR,
Hochster HS, Stein SM and Lacy J: FOLFIRINOX for locally advanced
and metastatic pancreatic cancer: single institution retrospective
review of efficacy and toxicity. Med Oncol. 30:3612013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee KA, Kang HW, Ahn JH, Suk HJ and Kim H:
Dysarthria induced by irinotecan in a patient with colorectal
cancer. Am J Health Syst Pharm. 70:1140–1143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
SevillaGarcia I, Rueda A and Alba E:
Irinotecan-induced central nervous system toxicity: a case report.
J Natl Cancer Inst. 91:6471999. View Article : Google Scholar
|
|
8
|
Baz DV, Bofill JS and Nogueira JA:
Irinotecan-induced dysarthria. J Natl Cancer Inst. 93:1419–1420.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ceccaldi B, Kara F, MommejaMarin H, Bègue
M, Saint Blancard P, Le Marec E and Hauteville D: Dysarthria during
irinotecan administration. Rev Med Interne. 23:950–951. 2002.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DeMarco S, Squilloni E, Vigna L,
Bertagnolio MF and Sternberg CN: Irinotecan chemotherapy associated
with transient dysarthria and aphasia. Ann Oncol. 15:1147–1148.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamberg P, Donders RC and Ten Bokkel
Huinink D: Central nervous system toxicity induced by irinotecan. J
Natl Cancer Inst. 98:2192006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gomez JA, Sanchez I and Ramirez JA:
Irinotecan-induced dysarthria: an insight into its pathogenesis?
Gastrointest Cancer Res. 2:209–210. 2008.PubMed/NCBI
|
|
13
|
Dressel AJ, van der Mijn JC, Aalders IJ,
Rinkel RN and van der Vliet HJ: Irinotecan-induced dysarthria. Case
Rep Oncol. 5:47–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harel M, Hyatt JL, Brumshtein B, Morton
CL, Yoon KJ, Wadkins RM, Silman I, Sussman JL and Potter PM: The
crystal structure of the complex of the anticancer prodrug
7-ethyl-10-[4-(1-piperidino)-1piperidino]-carbonyloxycamptothecin
(CPT-11) with Torpedo californica acetylcholinesterase provides a
molecular explanation for its cholinergic action. Mol Pharmacol.
67:1874–1881. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haxhiu MA, Mitra J, van Lunteren E, Bruce
EN and Cherniack NS: Hypoglossal and phrenic responses to
cholinergic agents applied to ventral medullary surface. Am J
Physiol. 247:R939–R944. 1984.PubMed/NCBI
|
|
16
|
Cortes R, Probst A and Palacios JM:
Quantitative light microscopic autoradiographic localization of
cholinergic muscarinic receptors in the human brain: brainstem.
Neuroscience. 12:1003–1026. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Falcone A, Ricci S, Brunetti I, Pfanner E,
Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W,
Fanchini L, et al: Phase III trial of infusional fluorouracil,
leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with
infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as
first-line treatment for metastatic colorectal cancer: The Gruppo
Oncologico Nord Ovest. J Clin Oncol. 25:1670–1676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Souglakos J, Androulakis N, Syrigos K,
Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S,
Kouroussis Ch, Vamvakas L, et al: FOLFOXIRI (folinic acid,
5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic
acid, 5-fluorouracil and irinotecan) as first-line treatment in
metastatic colorectal cancer (MCC): a multicenter randomized phase
III trial from the Hellenic oncology research group (HORG). Br J
Cancer. 94:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Masi G, Loupakis F, Salvatore L, Fornaro
L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso
D, et al: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin,
fluorouracil and folinate) as first-line treatment for metastatic
colorectal cancer: a phase 2 trial. Lancet Oncol. 11:845–852. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park SB, Lin CS, Krishnan AV, Goldstein D,
Friedlander ML and Kiernan MC: Oxaliplatin-induced neurotoxicity:
Changes in axonal excitability precede development of neuropathy.
Brain. 132:2712–2723. 2009. View Article : Google Scholar : PubMed/NCBI
|
